VSIR and pancreatic neoplasm: For pancreatic cancer patients, VISTA has been seen as a promising target for immunotherapeutic interventions based on the latest results revealed by Blando et al. They showed VISTA is an immune checkpoint particularly expressed in pancreatic cancer at higher rates [98].